1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > CNS Drug News 01 DECEMBER 2014

CNS Drug News 01 DECEMBER 2014

  • December 2014
  • -
  • Espicom Business Intelligence
  • -
  • 20 pages

Industry Trend Analysis - FDA-Approved Hysingla ER Places Pressure On Zohydro ER
Industry Brief - Cynapsus Reports Positive Top-Line Phase II Results For Off Episodes In PD
Industry Trend Analysis - AstraZeneca/Lilly's Alzheimer's Phase II/III Study Is High Risk/High Reward
Industry Brief - Forward Pharma Sues Biogen Idec Over Tecfidera Sales In Germany
Industry Brief - Pharmsynthez Completes First Patient Cohort In MyeloXen Phase II Study For MS
Industry Brief - Forward Pharma Receives Issue Notification For Erosion Matrix Patent In US
Industry Brief - Isis Initiates ISIS-SMNRx Phase III Study In Children With SMA; Earns Milestone
Industry Brief - Bio Blast's Cabaletta Receives FDA ODD For SCA3
Industry Brief - EMA Grants Treeway's TW001 ODD For ALS
Industry Brief - Soliris Granted ODD In Japan For NMO
Industry Brief - IntelGenx Settles US Bupropion Litigation With Wockhardt
Industry Trend Analysis - Mallinckrodt Sues After FDA Casts Doubt On Concerta Generics
Industry Brief - Janssen Submits NDA To FDA For Three-Month Paliperidone Palmitate
Industry Brief - First Patient Enrolled In Phase III Trial Of ITI-007 For Schizophrenia
Industry Brief - Insys' Pharmaceutical CBD Receives FDA ODD For Paediatric Schizophrenia
Industry Brief - Highland Receives Second NoA For Patent On HLD-200
Industry Trend Analysis - Avanir's Inhaled Migraine Therapy Is Delayed But Will Gain FDA Approval
Industry Brief - BfArM Accepts Rizaport MAA For Review
Industry Brief - Trevena Reports Positive Top-Line Results From TRV130 Phase IIa/b Study
Industry Brief - Camurus/Braeburn Sign Exclusive Licence For Long-Acting Buprenorphine Injectables
Industry Brief - NICE Issues Positive Final Guidance For Selincro
Industry Brief - Enrolment Completed In Probuphine Phase III Study For Opioid Dependence
Industry Brief - UCB/Daiichi Sankyo To Jointly Commercialise Lacosamide In Japan
Industry Brief - Eisai Launches Fycompa In Hong Kong
Industry Brief - Supernus Files Topiramate Lawsuit Against Zydus
Industry Brief - Orexigen Receives Allowance Of New US Patent For Contrave
Industry Brief - Two Additional US Patents Issued For Vivus' Qsymia
Industry Brief - Otsuka To Acquire Avanir Pharmaceuticals
Industry Brief - Wiinberg Resigns As CEO Of Lundbeck
Industry Brief - Bukwang Acquires Danish Bio-Venture Contera Pharma
Industry Brief - Shire To Relocate Over 500 Jobs To Massachusetts; Interim CFO Appointed

Table Of Contents

CNS Drug News 01 DECEMBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Alcoholism and drug dependence and addiction, known as substance use disorders and rehabilitation treatments are classified as substance abuse treatment. Some of the common symptoms of drug abuse are ...

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • August 2016
  • by Industry ARC

Psychotherapeutic drugs are used to treat mental illnesses such as extreme mood swings, social withdrawal, long lasting depression, confused thinking, and suicidal thought. schizophrenia, bipolar disorder, ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.